Fate Therapeutics, Inc. Stock price

Equities

FATE

US31189P1021

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-23 pm EST 5-day change 1st Jan Change
6.96 USD +1.16% Intraday chart for Fate Therapeutics, Inc. -7.94% +86.10%
Sales 2023 * 63.4M Sales 2024 * 5.97M Capitalization 678M
Net income 2023 * -168M Net income 2024 * -213M EV / Sales 2023 * 7.82 x
Net cash position 2023 * 183M Net cash position 2024 * 90.16M EV / Sales 2024 * 98.5 x
P/E ratio 2023 *
-4.01 x
P/E ratio 2024 *
-3.37 x
Employees 551
Yield 2023 *
-
Yield 2024 *
-
Free-Float 98.56%
More Fundamentals * Assessed data
Dynamic Chart
Fate Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors CI
Fate Therapeutics, Inc.(NasdaqGM:FATE) dropped from NASDAQ Biotechnology Index CI
Mizuho Lowers Price Target on Fate Therapeutics to $8 From $12, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Fate Therapeutics to $3 From $5, Maintains Equalweight Rating MT
Wells Fargo Trims Price Target on Fate Therapeutics to $5 From $6, Maintains Equalweight Rating MT
Wedbush Lowers Fate Therapeutics' Price Target to $3 From $6, Maintains Neutral Rating MT
Transcript : Fate Therapeutics, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Fate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Aura Biosciences Appoints New Chief Medical Officer MT
Fate Therapeutics, Inc.(NasdaqGM:FATE) dropped from S&P Biotechnology Select Industry Index CI
Morgan Stanley Adjusts Price Target on Fate Therapeutics to $5 From $8, Keeps Equalweight Rating MT
Barclays Adjusts Fate Therapeutics Price Target to $6 From $12, Maintains Overweight Rating MT
BMO Capital Adjusts Price Target on Fate Therapeutics to $5.40 From $6, Maintains Market Perform Rating MT
Wedbush Trims Fate Therapeutics' Price Target to $6 From $7, Keeps Neutral Rating MT
Transcript : Fate Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023
More news
1 day+1.16%
1 week-7.94%
Current month+12.99%
1 month+44.10%
3 months+194.92%
6 months+156.83%
Current year+86.10%
More quotes
1 week
6.47
Extreme 6.465
7.60
1 month
4.40
Extreme 4.4
7.74
Current year
3.46
Extreme 3.455
7.74
1 year
1.63
Extreme 1.63
7.74
3 years
1.63
Extreme 1.63
100.74
5 years
1.63
Extreme 1.63
121.16
10 years
1.46
Extreme 1.46
121.16
More quotes
Managers TitleAgeSince
Founder 53 07-04-26
Director of Finance/CFO 49 20-08-16
Chairman 75 11-10-31
Members of the board TitleAgeSince
Director/Board Member 69 14-03-16
Director/Board Member 61 20-04-30
Director/Board Member 57 13-07-31
More insiders
Date Price Change Volume
24-02-22 6.88 +0.73% 1,941,435
24-02-21 6.83 -3.26% 2,046,886
24-02-20 7.06 -6.61% 2,889,614
24-02-16 7.56 +6.78% 2,562,500
24-02-15 7.08 +9.09% 2,974,898

Delayed Quote Nasdaq, February 23, 2024 at 04:00 pm EST

More quotes
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of programmed cellular immunotherapies for patients with cancer and autoimmune disorders. It uses human induced pluripotent stem cells (iPSCs) generated from its iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The Company is advancing a pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted natural killer (NK) and T-cell product candidates. The Company's product pipeline includes FT576, FT819, FT825 and FT522. Its FT576, is an iPSC-derived, B-cell maturation antigen (BCMA)-targeted CAR NK cell product candidate for the treatment of multiple myeloma. Its FT819, is an iPSC-derived CAR T-cell therapy candidate, which is in Phase I study for the treatment of adult patients with relapsed / refractory B-cell malignancies, including B-cell lymphoma and chronic lymphocytic leukemia.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
6.88 USD
Average target price
6.344 USD
Spread / Average Target
-7.79%
Consensus
1st Jan change Capi.
+86.10% 678 M $
+5.71% 110 B $
+11.72% 104 B $
+9.93% 23 902 M $
-10.96% 22 243 M $
-26.36% 21 573 M $
-6.59% 18 925 M $
-13.93% 16 036 M $
+1.84% 13 271 M $
+41.59% 12 608 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock Fate Therapeutics, Inc. - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer